Natural killer cell-based cancer immunotherapy: from basics to clinical trials

被引:10
作者
Shi, Yinghong [1 ,2 ]
Hao, Donglin [1 ]
Qian, Hui [1 ,2 ]
Tao, Zhimin [1 ,2 ,3 ]
机构
[1] Jiangsu Univ, Wujin Hosp, Wujin Inst Mol Diagnost & Precis Canc Med, Changzhou 213017, Jiangsu, Peoples R China
[2] Jiangsu Univ, Sch Med, Jiangsu Prov Key Lab Med Sci & Lab Med, Zhenjiang 212013, Jiangsu, Peoples R China
[3] Jiangsu Univ, Dept Emergency Med, Affiliated Hosp, Zhenjiang 212001, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Natural killer cells; Immunotherapy; Tumor microenvironment; Chimeric antigen receptor; Clinical trial; INNATE LYMPHOID-CELLS; GAMMA RECEPTOR-III; REGULATORY T-CELLS; RESIDENT NK CELLS; IN-VIVO EXPANSION; CAR NK-92 CELLS; ANTITUMOR-ACTIVITY; SOLID TUMORS; PHASE-I; EXTRACELLULAR VESICLES;
D O I
10.1186/s40164-024-00561-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cellular immunotherapy exploits the capacity of the human immune system in self-protection and surveillance to achieve the anti-tumor effects. Natural killer (NK) cells are lymphocytes of innate immune system and they display a unique inherent ability to identify and eliminate tumor cells. In this review, we first introduce the basic characteristics of NK cells in the physiological and pathological milieus, followed by a discussion of their effector function and immunosuppression in the tumor microenvironment. Clinical strategies and reports regarding NK cellular therapy are analyzed in the context of tumor treatment, especially against solid tumors. Given the widely studied T-cell therapy in the recent years, particularly the chimeric antigen receptor (CAR) T-cell therapy, we compare the technical features of NK- and T-cell based tumor therapies at the clinical front. Finally, the technical challenges and potential solutions for both T and NK cell-based immunotherapies in treating tumor malignancies are delineated. By overviewing its clinical applications, we envision the NK-cell based immunotherapy as an up-and-comer in cancer therapeutics.
引用
收藏
页数:26
相关论文
共 214 条
[51]   Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer [J].
Daher, May ;
Rezvani, Katayoun .
CANCER DISCOVERY, 2021, 11 (01) :45-58
[52]  
Dai HR, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00856-8
[53]   Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy [J].
Dang, Bao-Toan Nguyen ;
Kwon, Taeg Kyu ;
Lee, Sooyeun ;
Jeong, Jee-Heon ;
Yook, Simmyung .
JOURNAL OF CONTROLLED RELEASE, 2024, 365 :773-800
[54]   Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy [J].
Davis, Zachary B. ;
Vallera, Daniel A. ;
Miller, Jeffrey S. ;
Felices, Martin .
SEMINARS IN IMMUNOLOGY, 2017, 31 :64-75
[55]   Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells [J].
de Andrade, Lucas Ferrari ;
Kumar, Sushil ;
Luoma, Adrienne M. ;
Ito, Yoshinaga ;
da Silva, Pedro Henrique Alves ;
Pan, Deng ;
Pyrdol, Jason W. ;
Yoon, Charles H. ;
Wucherpfennig, Kai W. .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (06) :769-780
[56]   Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity [J].
de Andrade, Lucas Ferrari ;
Tay, Rong En ;
Pan, Deng ;
Luoma, Adrienne M. ;
Ito, Yoshinaga ;
Badrinath, Soumya ;
Tsoucas, Daphne ;
Franz, Bettina ;
May, Kenneth F., Jr. ;
Harvey, Christopher J. ;
Kobold, Sebastian ;
Pyrdol, Jason W. ;
Yoon, Charles ;
Yuan, Guo-Cheng ;
Hodi, F. Stephen ;
Dranoff, Glenn ;
Wucherpfennig, Kai W. .
SCIENCE, 2018, 359 (6383) :1537-+
[57]   Markers and Function of Human NK Cells in Normal and Pathological Conditions [J].
Del Zotto, Genny ;
Marcenaro, Emanuela ;
Vacca, Paola ;
Sivori, Simona ;
Pende, Daniela ;
Della Chiesa, Mariella ;
Moretta, Francesca ;
Ingegnere, Tiziano ;
Mingari, Maria Cristina ;
Moretta, Alessandro ;
Moretta, Lorenzo .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2017, 92 (02) :100-114
[58]   CIS is a potent checkpoint in NK cell-mediated tumor immunity [J].
Delconte, Rebecca B. ;
Kolesnik, Tatiana B. ;
Dagley, Laura F. ;
Rautela, Jai ;
Shi, Wei ;
Putz, Eva M. ;
Stannard, Kimberley ;
Zhang, Jian-Guo ;
Teh, Charis ;
Firth, Matt ;
Ushiki, Takashi ;
Andoniou, Christopher E. ;
Degli-Esposti, Mariapia A. ;
Sharp, Phillip P. ;
Sanvitale, Caroline E. ;
Infusini, Giuseppe ;
Liau, Nicholas P. D. ;
Linossi, Edmond M. ;
Burns, Christopher J. ;
Carotta, Sebastian ;
Gray, Daniel H. D. ;
Seillet, Cyril ;
Hutchinson, Dana S. ;
Belz, Gabrielle T. ;
Webb, Andrew I. ;
Alexander, Warren S. ;
Li, Shawn S. ;
Bullock, Alex N. ;
Babon, Jeffery J. ;
Smyth, Mark J. ;
Nicholson, Sandra E. ;
Huntington, Nicholas D. .
NATURE IMMUNOLOGY, 2016, 17 (07) :816-+
[59]   Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells [J].
Denman, Cecele J. ;
Senyukov, Vladimir V. ;
Somanchi, Srinivas S. ;
Phatarpekar, Prasad V. ;
Kopp, Lisa M. ;
Johnson, Jennifer L. ;
Singh, Harjeet ;
Hurton, Lenka ;
Maiti, Sourindra N. ;
Huls, M. Helen ;
Champlin, Richard E. ;
Cooper, Laurence J. N. ;
Lee, Dean A. .
PLOS ONE, 2012, 7 (01)
[60]   Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy [J].
Di Stasi, Antonio ;
Tey, Siok-Keen ;
Dotti, Gianpietro ;
Fujita, Yuriko ;
Kennedy-Nasser, Alana ;
Martinez, Caridad ;
Straathof, Karin ;
Liu, Enli ;
Durett, April G. ;
Grilley, Bambi ;
Liu, Hao ;
Cruz, Conrad R. ;
Savoldo, Barbara ;
Gee, Adrian P. ;
Schindler, John ;
Krance, Robert A. ;
Heslop, Helen E. ;
Spencer, David M. ;
Rooney, Cliona M. ;
Brenner, Malcolm K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) :1673-1683